CompletedPhase 3NCT00004690

Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis

Studying Congenital ichthyosiform erythroderma

Last synced from ClinicalTrials.gov May 22, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cellegy Pharmaceuticals
Principal Investigator: Carl R. Thornfeldt, MD
Cellegy Pharmaceuticals
Intervention: monolaurin cream(drug)
Enrollment: 90 enrolled
Eligibility: 2 years · All sexes
Timeline: 1996 – 1998

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00004690 on ClinicalTrials.gov

Other trials for Congenital ichthyosiform erythroderma

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2, PHASE3NCT07538583
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Quoin Pharmaceuticals
ENROLLING BY INVITATIONNCT03417856
Defining the Skin and Blood Biomarkers of Ichthyosis
Northwestern University

See all trials for Congenital ichthyosiform erythroderma →

← Back to all trials